

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

1.-45. (canceled)

46. (currently amended) A method for preventing or reducing chronic cardiotoxicity caused by a chemotherapeutic agent in a subject in need of such a treatment, comprising administering to the subject a 4-1BB antagonist in an amount sufficient to prevent or reduce the cardiotoxicity, wherein the 4-1BB antagonist is selected from the group consisting of a soluble 4-1BB protein that blocks or reduces the interaction of 4-1BB and 4-1BB-L, an antibody that specifically binds 4-1BB and blocks or reduces the interaction of 4-1BB and 4-1BB-L, and an antibody that specifically binds 4-1BB-L and blocks or reduces the interaction of 4-1BB and 4-1BB-L.

47. (previously presented) The method according to Claim 46, wherein the cardiotoxicity is cardiomyopathy.

48. (previously presented) The method according to Claim 46, wherein the chemotherapeutic agent is an anthracycline drug.

49. (previously presented) The method according to Claim 48, wherein the anthracycline drug is doxorubicin.

50. (canceled)

51. (currently amended) The method of Claim 5046, wherein the 4-1BB antagonist is soluble 4-1BB protein, and further wherein said soluble 4-1BB protein is an Fc fusion protein.

52. (previously presented) The method of Claim 46, wherein the subject is a cancer patient.

53.-63. (canceled)

64. (currently amended) The method of Claim 6346, wherein the soluble 4-1BB protein is an oligomer.

65. (currently amended) The method of Claim 63~~46~~, wherein the soluble 4-1BB protein comprises amino acids 1-163 of SEQ ID NO: 18.

66. (previously presented) The soluble 4-1BB protein of Claim 64, wherein the protein comprises amino acids 1-163 of SEQ ID NO: 18.

67. (previously presented) The soluble 4-1BB protein of Claim 51, wherein the protein comprises amino acids 1-163 of SEQ ID NO: 18.